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Abstract
Acute kidney injury (AKI) affects roughly 25% of all recipients of deceased donor organs. The prevention of post-transplant
AKI is still an unmet clinical need. We prospectively collected zero-hour, indication as well as protocol kidney biopsies from
166 allografts between 2011 and 2013. In this cohort eight cases with AKI and ten matched allografts without pathology
serving as control group were identified with a follow-up biopsy within the first twelve days after engraftment. For this set
the zero-hour and follow-up biopsies were subjected to genome wide microRNA and mRNA profiling and analysis, followed
by validation in independent expression profiles of 42 AKI and 21 protocol biopsies for strictly controlling the false discovery
rate. Follow-up biopsies of AKI allografts compared to time-matched protocol biopsies, further baseline adjustment for zero-
hour biopsy expression level and validation in independent datasets, revealed a molecular AKI signature holding 20 mRNAs
and two miRNAs (miR-182-5p and miR-21-3p). Next to several established biomarkers such as lipocalin-2 also novel
candidates of interest were identified in the signature. In further experimental evaluation the elevated transcript expression
level of the secretory leukocyte peptidase inhibitor (SLPI) in AKI allografts was confirmed in plasma and urine on the protein
level (p,0.001 and p= 0.003, respectively). miR-182-5p was identified as a molecular regulator of post-transplant AKI,
strongly correlated with global gene expression changes during AKI. In summary, we identified an AKI-specific molecular
signature providing the ground for novel biomarkers and target candidates such as SLPI and miR-182-5p in addressing AKI.
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Introduction
Post-transplant acute kidney injury (AKI) is a frequent
complication after kidney transplantation and is associated with
shortened graft survival [1,2,3]. In spite of a remarkable progress
in the field of transplantation medicine, the incidence of AKI over
the last 20 years remained constant. Rates between 15 and 25%
have been reported, which mainly depend on the definition of
AKI but also showing substantial differences between centers
[4,5].
Several risk factors contributing to the development of AKI
after kidney transplantation have been identified, including donor
age, prolonged cold and warm ischemic times, and the use of
organs procured from non-heart beating donors [5,6]. Molecular
mechanisms determining the fate of kidney allografts via triggering
the development of AKI remain unclear as ischemia and
reperfusion injury (IRI) occur at a varying degree in all
transplanted organs.
Molecular and cellular alterations associated with IRI mainly
include tissue damage caused by reactive oxygen species (ROS),
nitric oxide or peroxynitrite [7], but also a decreased adenylate
cyclase activity and consecutive low intracellular cAMP levels.
Consequences are impaired endothelial cell barrier functions
(vascular permeability and leakage) [8,9]. Furthermore, significant
alterations at the transcriptional level in control of gene expression
occur, such as upregulation of the hypoxia inducible factor 1A
(HIF1A) or the nuclear factor kappa B (NF-kB), the central
regulator of inflammatory response [10]. Later on in the response
cascade of IRI, cell death via apoptosis and necrosis is triggered
[11]. Additionally, the activation of innate and adaptive immune
response is provoked and contributes to tissue damage and injury,
comprising pattern recognition receptors (PRRs) such as Toll-like
receptors (TLRs) and/or infiltration of macrophages and/or T-
cells [12].
Furthermore, microRNAs (miRNAs) were identified to be
involved in the molecular cascade following IRI. miRNAs are
post-transcriptional modulators that regulate target genes by
perfect- or semi-complementary base pairing, finally resulting in
RNA degradation or inhibition of translation, respectively [13].
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Godwin et al. and Shapiro et al. reported miRNA signatures after
warm ischemia followed by reperfusion in mice kidneys [14,15],
and our group recently showed a deregulation of miRNAs in
human post-transplantation (TX) AKI biopsies [16]. However,
our knowledge on how miRNAs regulate gene expression in
injured kidney tissue and impact transcript and protein levels is
fairly understood.
This study was designed to specifically elucidate molecular
regulation patterns on the combined level of mRNA and
microRNA expression of transplant kidneys diagnosed with AKI
versus grafts showing prompt organ function.
Materials and Methods
Renal transplant biopsy specimen
The study protocol was approved by the Institutional Review
Board (IRB) (Ethical Committee of the Semmelweis University
Budapest # 20303-0/2010-1018EKU (821/PI/01)), and all
recipients provided written informed consent to follow-up allograft
biopsy and blood and urine samples for research. There was no
need for informed consent for zero-hour biopsies from deceased
donor organs according to the IRB protocol, as allowance to
perform autopsy existed. Living donors gave written informed
consent to zero-hour donor biopsy for research.
We prospectively collected zero-hour biopsies from 166 renal
allograft recipients from March 2011 to April 2013. From these
166 recipients, 34 had a follow-up kidney biopsy within 12 days
after transplantation with the following clinical conditions: (i) 16
rejections (eight Banff 1, two Banff 2, one antibody-mediated
rejection, two Banff 1 rejections with humoral rejection signs and
three Banff Borderline rejections), (ii) eight with acute tubular
necrosis without rejection defined as AKI and (iii) ten protocol
biopsies without pathology acting as control group (primary graft
function). AKI was defined as acute tubular necrosis in the absence
of cellular and/or humoral signs of rejection according to the
Banff 2012 criteria [17]. The indication for AKI kidney biopsy was
more than one dialysis session within the first week after
transplantation and a serum creatinine above 4 mg/dL after the
first week. Together with the post-TX biopsies, EDTA-plasma and
urine was collected from the recipients. The biopsy specimens
were immediately submerged in RNAlaterTM (Ambion, Austin,
Texas, USA) ensuring maximal RNA quality. For the present
study we used (i) eight biopsy pairs with histological lesions of acute
tubular necrosis in the post-TX biopsies (AKI group) and (ii) ten
allografts with primary function and protocol biopsies without
pathology (PGF group).
RNA Extraction and Microarray Hybridization
Total RNA was isolated and purified using chloroform and
trizol reagent (Invitrogen, Carlsbad, California USA). RNA yield
and quality were checked with the Agilent 2100 Bioanalyzer
(Agilent, Palo Alto, California, USA). Kidney mRNA expression
analysis was performed according to the NuGEN-recommended
protocol using the Affymetrix GeneChip Human Gene 2.0 ST
Array. Affymetrix GeneChip miRNA 3.0 Arrays were used for
miRNA profiling. Total RNA (1 mg per sample) was labeled using
the FlashTagTM Biotin HSR RNA Labeling Kit (Affymetrix,
Santa Clara, California, USA) and hybridized to the arrays as
described by the manufacturer.
miRNA and mRNA microarray analysis
Affymetrix data were pre-processed, normalized, and summa-
rized using the robust multi-average (RMA) method with quantile
normalization, and annotated using the corresponding annotation
file (.cdf) in Bioconductor. Microarray raw data files are available
in the Gene Expression Omnibus (GEO) at NCBI with the
accession number GSE53773. Interquartile range and intensity
filtering were used to exclude features with low variance and signal
intensity (log2 level ,4) over all profiles [18]. Significance Analysis
of Microarrays (SAM) was used to determine differentially
regulated mRNAs and miRNAs comparing AKI and control
group samples [19]. The false discovery rate (FDR) was set to ,
10% and the minimum fold change to 1.5 in order to detect
significantly differentially regulated transcripts. Further, the
derived mRNA and miRNA AKI signatures were verified in
independent datasets [16,20]. Principal component analysis was
performed based on the covariance matrix to visualize the
variance in the gene expression signatures of the allografts.
Spearman correlation was applied to evaluate association of
differentially regulated miRNAs and mRNAs. Functional group-
ing of genes was based on Gene Ontology (GO) terms utilizing the
DAVID Functional Annotation platform [21]. Three algorithms
were used to predict miRNA targets, namely DIANAmT,
miRanda and Targetscan [22,23,24]. Only miRNA targets
identified by all three prediction algorithms were included in
further analysis. Additionally, experimentally validated targets
were extracted for identified miRNAs from miRTarBase [25].
To extract biomarker candidates discussed in the context of
AKI the text mining tool FABLE (http://fable.chop.edu/
overview.jsp) was used [26], taking into account all genes having
at least two scientific references with the following search terms:
‘Acute kidney injury’ and ‘Biomarker’.
Quantitation of SLPI protein concentration
We used a quantitative sandwich enzyme-linked immunoassay
(ELISA) to determine the protein concentration of SLPI in plasma
and urine as described by the manufacturer (R&D Systems,
Minneapolis, MN, USA, article# DPI00).
Statistical analysis of clinical data
Continuous data were analyzed by non-parametric Wilcoxon
Rank Sum Test. Categorical data were evaluated by Chi-square
test or Fisher’s exact test where appropriate. A p-value below 0.05
was considered statistically significant. Statistical assessment was
performed with SAS for Windows 9.3 (The SAS Institute, Inc.,
Cary, North Carolina, USA).
Results
Patient characteristics
We first analyzed two sequential biopsies in 18 different kidney
grafts (Basic mRNA and miRNA dataset). The first biopsy was
carried out at implantation after cold storage (zero-hour biopsy)
and the second biopsy was taken within 12 days after transplan-
tation. Eight allografts fulfilled histological criteria for acute
tubular injury in the post-TX biopsy (AKI group), and the other
ten allografts had primary graft function (PGF) serving as control
group with no pathology in the post-TX biopsy (protocol biopsy).
Demographic data on the 18 transplant donors and recipients are
provided in Table 1. None of the demographic variables of the
recipient and donor pairs were significantly different between the
two groups. Median donor age was numerically higher in the AKI
group (53 years; interquartile range (IQR): [46.8; 56.8]) when
compared to the PGF group (42.3 years; IQR: [40.3; 50],
p=0.28). All deceased donors received catecholamines before
organ retrieval. Median serum creatinine level at time of post-TX
biopsy was 9.81 mg/dL in the AKI group and 1.54 mg/dL in the
PGF group (p,0.001). Independent publicly available mRNA and
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miRNA datasets were used for validation of findings in the Basic
mRNA and miRNA dataset. The independent mRNA dataset
comprised renal post-TX biopsies from allografts diagnosed with
AKI (n= 28) and six week protocol biopsies (n = 11) published by
Famulski et al. in 2012 [20] and the independent miRNA dataset
consisted of miRNA profiles of AKI post-TX biopsies (n = 14) and
three-month protocol biopsies (n = 10) from one of our previous
studies [16]. Patient characteristics from these published datasets
were extracted from the original publications and are also
provided in Table 1. A significant difference was found in biopsy
collection time between the AKI and protocol biopsy groups and
no zero-hour biopsies were collected in these studies. Variables not
found in the original publications are indicated as ‘not stated’.
Molecular phenotype of post-transplant AKI
Differentially regulated genes in the injured kidney. In a
first analysis we compared mRNA profiles of post-TX biopsies
between the AKI (n= 8) and PGF group (n = 10) using the SAM
method setting the FDR to ,10%. In total, 245 differentially
regulated genes were identified showing fold changes .1.5 (Table
Table 2. AKI mRNA signature as verified in the independent evaluation dataset.
post-TX baseline adjusted
Probe Set ID Gene Symbol raw p-value Fold change raw p-value Fold change Gene Description
16919547 SLPI 1.55E-03 5.67 1.20E-03 15.17 secretory leukocyte peptidase inhibitor
16775083 OLFM4 6.15E-03 2.86 2.98E-03 7.88 olfactomedin 4
16787902 SERPINA3 1.08E-03 2.03 2.91E-03 7.03 serpin peptidase inhibitor, clade A (alpha-
1 antiproteinase, antitrypsin), member 3
16743647 MMP7 3.42E-02 2.88 1.54E-02 4.06 matrix metallopeptidase 7
(matrilysin, uterine)
16760792 CD163 2.77E-02 1.94 1.69E-02 3.12 CD163 molecule
16693414 S100A8 7.43E-04 2.40 1.66E-02 3.09 S100 calcium binding protein A8
16735751 LYVE1 7.55E-04 1.53 2.09E-03 2.28 lymphatic vessel endothelial hyaluronan
receptor 1
17089525 LCN2 5.02E-03 1.95 8.81E-03 2.28 lipocalin 2
16707503 EXOC6 8.75E-04 1.52 1.88E-03 1.78 exocyst complex component 6
17024144 IFNGR1 4.61E-03 1.51 7.64E-03 1.77 interferon gamma receptor 1
17087615 LPPR1 5.54E-04 0.51 3.00E-03 0.57 lipid phosphate phosphatase-related
protein type 1
16991527 CYFIP2 2.00E-03 0.55 2.80E-03 0.52 cytoplasmic FMR1 interacting protein 2
16695262 KCNJ10 3.92E-04 0.55 3.00E-04 0.52 potassium inwardly-rectifying channel,
subfamily J, member 10
17101262 ARSF 1.46E-03 0.57 3.30E-03 0.47 arylsulfatase F
17094946 TRPM6 1.89E-02 0.62 2.19E-03 0.45 transient receptor potential cation
channel, subfamily M, member 6
17072059 SLC30A8 2.29E-02 0.53 4.78E-03 0.45 solute carrier family 30 (zinc transporter),
member 8
16773086 FGF9 4.37E-04 0.55 8.50E-04 0.45 fibroblast growth factor 9 (glia-activating
factor)
16934643 PVALB 2.02E-04 0.39 2.75E-03 0.42 parvalbumin
17007950 PNPLA1 1.15E-03 0.50 1.10E-03 0.36 patatin-like phospholipase domain
containing 1
16962671 TMEM207 1.57E-04 0.32 9.31E-04 0.33 transmembrane protein 207
bold......molecular features discussed as biomarker candidates of acute kidney injury.
Raw p-values and fold changes of verified differentially regulated genes are provided.
doi:10.1371/journal.pone.0104164.t002
Table 3. AKI miRNA signature as verified in the evaluation dataset.
post-TX baseline adjusted
Probe Set ID miRNA Name miRBase Accession raw p-value Fold change raw p-value Fold change
hsa-miR-21-star_st hsa-miR-21-3p MIMAT0004494 1.64E-02 2.22 2.41E-02 3.34
hsa-miR-182_st hsa-miR-182-5p MIMAT0000259 1.62E-02 1.56 2.46E-03 1.88
Raw p-values and fold changes of verified differentially regulated miRNAs are provided.
doi:10.1371/journal.pone.0104164.t003
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S1). Based on the 245 differentially regulated genes, principal
component analysis (PCA) was performed. Samples were clustered
utilizing the first three principal components that captured over
85% of the variance in the dataset (Figure S1).The 18 allografts
separated into two distinct clusters in line with pathology stages,
indicating that AKI allografts could be characterized based on the
245 differentially regulated genes. Functional annotation of the
245 genes revealed several significantly over-represented biological
processes such as ‘response to wounding’, ‘response to toxin’, or
‘response to metal ion and oxidation-reduction’ (Table S2).
In a second step we also factored the mRNA expression levels of
the zero-hour biopsies into the analysis by calculating the log2
expression difference between the two sequential biopsies of each
allograft, and then again comparing AKI allografts vs. allografts
with primary graft function (baseline adjustment). This analysis
allowed us to identify the expression level trajectory in the
development of AKI from implantation to the histological
diagnosis of AKI in the recipient. 39 genes of the initial set of
245 genes still showed significant deregulation on the transcript
level in the development of AKI (Table S3).
To assess the validity of the identified differentially regulated
genes we evaluated our results in the mRNA dataset from
Famulski et al., 2012 (GEO accession number: GSE30718) [20].
After re-analysis of this mRNA expression dataset utilizing the
same statistical workflow as applied for our profiles, 932 genes
were identified as significantly differentially regulated between the
28 AKI samples and 11 protocol biopsies without signs of AKI. A
significant overlap was observed for our set of 39 baseline-adjusted
AKI genes, with 20 also being present in the dataset from Famulski
et al. (Chi-square test, p,0.001, using the total number of shared
features on the Affymetrix arrays as reference, Table 2). The 20
shared genes could be categorized into the following biological
processes: (i) ‘response to wounding’ (LYVE1, S100A8, SER-
PINA3, CD163; p=0.02), (ii) ‘acute-phase response’ (SERPINA3,
CD163; p=0.04) and (iii) ‘inflammatory response’ (S100A8,
SERPINA3, CD163; p=0.04).
Several of these deregulated genes were shown to be AKI
biomarker candidates already discussed in the scientific literature
according to FABLE analysis (highlighted bold in the gene lists,
Table S1, S3 and Table 2), including MMP7, LCN2 and S100A8,
supporting the validity of the identified AKI signature (Table 2).
Differentially regulated miRNAs in AKI. Deregulated
miRNAs were identified following the same analysis workflow as
used for deriving the mRNA profiles. 49 microRNAs were
significantly upregulated in the AKI post-TX biopsies by more
than 1.5 fold (SAM, FDR ,10%, Table S4) compared to the PGF
group. miRNAs with significant down-regulation were not
detected. After expression baseline adjustment taking expression
levels of the zero-hour biopsies into account, 29 miRNAs
remained significantly differentially regulated (Table S5). For
verification of the identified miRNAs a dataset recently published
by our group was used (GEO accession number: GSE30282) [16].
We again re-analyzed this dataset by comparing miRNA profiles
of AKI post-TX biopsies (n = 14) and three-month protocol
Figure 1. Raw p-values and area under the curve (AUC) of the investigated mRNAs and miRNAs comparing post-TX AKI and PGF
allografts. (A) full p-value range of mRNAs (B) mRNAs with p-value,0.08 on the x-axis for specific visualization of features with a raw p-value,0.05
(C) full p-value range of microRNAs (D) microRNAs with raw p-value,0.08 on the x-axis; red: features verified in an independent dataset (20 mRNAs
and two microRNAs), green: significant features after baseline adjustment (39 mRNAs and 29 miRNAs), blue: significant features identified by SAM
(245 mRNAs and 49 microRNAs), black: remaining features (11,788 mRNAs and 393 microRNAs).
doi:10.1371/journal.pone.0104164.g001
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biopsies (n = 10) of kidneys with no AKI history, and identified
twelve miRNAs as significantly upregulated. Of these 12 miRNAs
from our validation set, two miRNAs (miR-21-3p and miR-182-
5p) were found in the baseline-adjusted list of 29 miRNAs
(Table 3). Only five out of the 29 differentially regulated miRNAs
were present as probes on the Affymetrix array that was used in
our validation dataset. Therefore an overlap of two miRNAs was
still statistically significant when taking into account the number of
common and valid probes of mature miRNAs on the two different
arrays (Fisher’s exact test, p = 0.03).
Figure 1 shows the raw p-values of the investigated mRNAs and
miRNAs resulting from the group comparisons of post-TX AKI
and PGF allografts plotted against the area under the curve (AUC)
of the receiver operating characteristic (ROC) curve computed for
each individual transcript. Significantly differentially regulated
mRNAs and miRNAs are highlighted in color. Indeed, baseline
adjustment and verification in an independent dataset led to
selection of features with a lower p-value and a higher AUC value,
strengthening the utility of our analysis approach.
MicroRNA-182-5p expression is correlated with global
gene expression response of post-transplant AKI
Spearman correlation was used to associate miRNA and mRNA
expression levels. Correlation coefficients of the verified miRNAs,
miR-21-3p and miR-182-5p, were calculated for the baseline-
adjusted mRNA expression levels and plotted against the raw p-
values of the mRNAs comparing AKI and PGF allografts
(Figure 2). Apparently, the expression levels of miR-182-5p
showed a more pronounced correlation with the differentially
regulated mRNAs as indicated by the funnel at lower p-values in
Figure 2B. Correlation with miR-21-3p expression levels did not
exhibit this effect (Figure 2A) suggesting a central role of miR-182-
5p in graft injury.
We identified three further miRNAs (miR-132-3p, miR-212-3p
and miR-149-3p) not being covered in the verification data set
with a similar correlation pattern as seen for miR-182-5p (Figure
S2). Together these four miRNAs are highly correlated (R,20.7
or .0.7) to 26 baseline adjusted differentially regulated mRNAs
(Table S6), which can be categorized into the biological processes
‘ECM-receptor interaction’ (p=0.004) and ‘Focal adhesion’
(p=0.02). Further two genes with a negative correlation coefficient
are potential direct targets of two miRNAs based on three miRNA
target prediction algorithms (DIANAmT, miRanda and TargetS-
can). miR-182-5p is predicted to be a potential inhibitor of klotho
(KL) and miR-149-3p of potassium inwardly-rectifying channel,
subfamily J, member 10 (KCNJ10). None of the correlated genes
were experimentally verified targets of the four miRNAs according
to miRTarBase.
Validation of a potential novel biomarker of AKI in
plasma and urine
To further assess the validity of our findings also on the protein
level, we selected the protein product of the gene revealing the
strongest association with AKI according to mRNA expression
fold change, namely the secretory leukocyte peptidase inhibitor
(SLPI). SLPI protein concentrations were determined in EDTA-
plasma and urine of the 18 kidney allograft recipients. EDTA
plasma and urine were collected at the same day as the post-TX
biopsy. For three AKI patients only plasma was available due to
lack of urine excretion. SLPI protein concentration was found to
be significantly elevated in plasma as well as in urine of AKI
patients when compared to the PGF group (Figure 3). Median
SLPI concentration in plasma was 117 ng/ml (IQR: [96; 132]) in
the AKI group and 71 ng/ml (IQR: [60; 72]) in the PGF group
(p,0.001, Figure 3A). In urine the SLPI concentration was
73 ng/ml (IQR: [25; 156]) in the AKI group (n= 5) and 3.6 ng/
ml (IQR: [2.5; 5.6]) in the PGF group (p=0.003, Figure 3B). SLPI
gene expression levels in the transplant kidneys were also highly
correlated with SLPI protein concentrations in urine (R=0.77)
and plasma (R=0.57), respectively. Relative gene expression of
SLPI in post-TX biopsies is shown in Figure 3C.
Discussion
This study provides a comprehensive molecular picture of post-
transplant AKI on the combined mRNA and miRNA level. As all
transplant organs experienced IRI, the comparison between AKI
and time-matched biopsies from allografts with primary function
within the first days after transplantation allowed us to investigate
the molecular profiles leading to poor initial graft function and
acute tubular injury. Several known as well as novel molecules
were identified.
The clinical consequences of post-transplant AKI leading to
delayed graft function (DGF) were extensively investigated. A
meta-analysis of 33 studies showed that recipients with DGF had
an increase of relative risk (RR) by 41% to lose their graft in a
median follow-up time of 3.2 years [2]. Further, DGF was
associated with an augmented rate of acute rejection episodes (RR
18%–66%) and higher serum creatinine levels at the end of the
follow-up period [2,27,28]. Therefore, prevention of DGF is of
significant medical relevance, especially regarding limited donor
pools and the acceptance of further marginal donor kidneys
[29,30,31,32].
Our current understanding of the molecular mechanisms
underlying post-transplant AKI is mainly based on investigations
of IRI [33] and of zero-hour kidney transplant biopsies [34,35,36].
To our knowledge only one study so far analyzed the
transcriptome of human renal allograft biopsies during AKI [20]
which was also used as independent validation set for findings of
the current study. Six-week protocol biopsies of allografts with no
history of AKI and stable kidney function (n= 11) served as the
control group in this study. The validation study for our miRNA
findings was based on protocol biopsies procured after three
months [16]. Aside these differences in follow-up time a significant
overlap of deregulated mRNAs and miRNAs was found, providing
us with a stable molecular AKI signature on mRNA and miRNA
level. Several biomarker candidates were found in the list of
differentially regulated genes, with some of them discussed as
prognostic markers regarding future graft function such as
lipocalin-2 (LCN2) and Kidney Injury Molecule 1 (HAVCR1)
[37,38,39], allowing to deduce an association with intrinsic injury
in the kidney linked to outcome. Hence, the consensus mRNA and
miRNA AKI signature may be utilized to establish biomarkers
providing a better approximation of the injury status in the organ.
We evaluated one of these candidates, SLPI, on the protein level in
plasma and urine of the transplant recipients. We could confirm
the significantly elevated SLPI mRNA expression in injured
allografts both in plasma and urine of AKI patients also on the
protein level. Furthermore SLPI urine concentration was highly
Figure 2. Correlation coefficients (Spearman’s rho) of (A) miR-21-3p and (B) miR-182-5p and mRNAs plotted against the
corresponding raw p-values of baseline adjusted mRNA levels comparing the AKI and PGF group.
doi:10.1371/journal.pone.0104164.g002
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correlated with SLPI gene expression in the organ, indicating a
link of elevated SLPI concentration in urine to the status of kidney
damage in the organ itself. Tubule epithelial cells have already
been identified by immunohistochemistry as the source of SLPI
protein expression in the kidney [40]. However, further evaluation
in larger patient cohorts is needed to assess the applicability of
SLPI as a novel biomarker for AKI.
On the molecular level the most challenging part is to
distinguish repair response from mechanisms causing devastating
injury in the donor organ and subsequent detrimental effects on
graft and patient survival. Final proof can only be accomplished in
functional studies of the involved molecules. However, unbiased
explorative analyses such as the present study are important for
discovery, hypothesis generation and refinement. Therapeutic
targets currently under investigation for DGF and IRI are
summarized in two recently published reviews [5,41]. Inhibition
of the Toll-like receptor 2 (TLR2) is one of the experimental
strategies (clinicaltrials.gov: NCT01794663). TLR signaling leads
to an accelerated immune response and can be activated by so
called ‘danger signals’ (i.e. from damaged tissue) [42]. We found a
higher expression of TLR2 in AKI allografts (Table S1).
miRNAs are currently under intense investigation as therapeu-
tic agents and potent modifiers of immune response and tolerance
[43]. miRNAs are shown to regulate entire molecular networks via
simultaneous targeting of several hundred genes [44]. This makes
miRNAs, in contrast to compounds targeting a single molecule,
interesting for clinical phenotypes such as AKI where entire
cellular processes are deregulated.
miR-182-5p expression is profoundly correlated with genes
identified to be strongly associated with kidney tissue injury. miR-
182-5p can be activated by IL2 and STAT5 and inhibits FOXO1
expression [45]. FOXO1 acts as a master cellular regulator of a
variety of cellular processes including cell survival, apoptosis,
proliferation and metabolism, and also plays a critical role in the
homeostasis of cells of the immune system including T-cells, B-cells
and neutrophils [46]. Further, the absence of FOXO1 was shown
to severely curtail the development of FOXP3+ regulatory T-cells
(Tregs). Those Tregs that nevertheless developed were found to be
non-functional in vivo and down-regulation of FOXO1 in T-cells
resulted in lymphocyte infiltration [47]. Further, BCL2 is a direct
target of miR-182-5p and inhibition of miR-182-5p resulted in a
higher protein expression of BCL2, suggesting potent anti-
apoptotic effects [48,49].
Certainly there are limitations in the interpretation of the given
kidney biopsy mRNA and miRNA profiles such as the limited
sample size, which we aimed to compensate by controlling the
FDR, and importantly via validation in independent sample
cohorts. Additionally we confirmed differentially regulation of
three mRNAs in the Basic dataset and two miRNAs in the
independent miRNA dataset by qRT-PCR (Figure S3). Further, as
microRNAs are post-transcriptional regulators which mainly
inhibit translation of mRNAs into proteins [44], we based the
identification of miRNA regulators on correlation analysis with the
corresponding mRNA profiles of each allograft. This allowed us to
capture the global impact on gene expression of the microRNA
regulators [50].
Taken together, an AKI-specific molecular signature on the
mRNA and miRNA level was identified. The identified molecules
and processes set the stage for subsequent injury specific
biomarker validation and functional studies uncovering the
relation to immune-associated damage and repair response. This
will lead to further improvement in understanding and potential
clinical management of AKI.
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Figure S1 Principal component analysis based on the
245 differentially regulated genes comparing post-TX
AKI and PGF allografts. The first three principal components
(PC) were plotted, capturing 85% of the variance in the dataset.
Acute kidney injury allografts (grey spheres) and allografts with
primary kidney function (black spheres) form two distinct clusters.
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Figure S2 Correlation coefficients (Spearman’s rho) of
(A) miR-132-3p and (B) miR-212-3p (C) miR-149-3p
calculated for all mRNAs against the raw p-values of
baseline adjusted mRNA levels between the AKI and
PGF group.
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Figure S3 qRT-PCR validation of significantly differen-
tially regulated (A) mRNAs (SLPI, MMP7 and LCN2) and
(B) miRNAs (miR-182-5p and miR-21-3p) between AKI
and control group (PGF). Log2 (relative expression) values are
shown for the qRT-PCR and the array experiment. Individual
data points as well as median, 1st and 3rd quartile are provided.
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Table S1 245 significantly differentially regulated
mRNAs comparing post-TX AKI and protocol biopsies
from allografts with primary graft function.
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Table S2 Significantly over-represented biological pro-
cesses embedded in the post-TX mRNA signature (245
mRNAs).
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Table S3 39 significantly differentially regulated
mRNAs comparing AKI and PGF allografts after base-
line adjustment.
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Table S4 Significantly differentially regulated miRNAs
comparing post-TX AKI and protocol biopsies from
allografts with primary graft function.
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Table S5 Significantly differentially regulated micro-
RNAs comparing AKI and PGF allografts after baseline
adjustment.
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Table S6 Highly correlated genes (Spearman’s rho.0.7
or ,20.7) to miR-182-5p, miR-132-3p, miR-212-3p and
miR-149-3p out of the baseline adjusted differentially
regulated gene list.
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Figure 3. SLPI protein concentration (ng/ml) measured by sandwich ELISA in (A) EDTA-plasma and (B) urine of AKI and PGF
patients. Three AKI patients were anuric at the time of post-TX biopsy. (C) Relative gene expression levels of SLPI in post-TX biopsies. Individual data
points as well as median, 1st and 3rd quartile are provided.
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